- Home
- ONB vs LEGN Comparison
ONB vs LEGN Comparison
Compare ONB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ONB | LEGN |
|---|---|---|
| Founded | 1834 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ONB | LEGN |
|---|---|---|
| Price | $22.96 | $22.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $26.09 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 2.8M | 2.3M |
| Earning Date | 01-20-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 2.73 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $2,110,915,000.00 | $909,045,000.00 |
| Revenue This Year | $45.73 | $68.83 |
| Revenue Next Year | $14.53 | $51.27 |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | 20.70 | ★ 74.75 |
| 52 Week Low | $16.83 | $21.19 |
| 52 Week High | $24.49 | $45.30 |
Technical Indicators
Market Signals| Indicator | ONB | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 33.52 |
| Support Level | $22.95 | $21.19 |
| Resistance Level | $23.59 | $23.24 |
| Average True Range (ATR) | 0.42 | 1.04 |
| MACD | -0.03 | 0.18 |
| Stochastic Oscillator | 57.45 | 21.26 |
Price Performance
Historical ComparisonAbout ONB Old National Bancorp
Old National Bancorp with almost $10 billion in assets following its latest acquisition, Old National Bancorp is a financial services bank holding company headquartered in Indiana. Based in Evansville, Ind., Old National owns multiple financial services operations in Indiana, Illinois, and Kentucky. The company provides a group of similar community banking services, including such products and services as commercial, real estate, and consumer loans; deposits; and brokerage, trust, and investment advisory services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.